SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
The Californer/10195477

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ: VRCA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between May 28, 2021 and May 24, 2022, inclusive (the ''Class Period''), are encouraged to contact the firm before August 5, 2022.

If you are a shareholder who suffered a loss, click here to participate.

More on The Californer

• EmailWarmup.com Offers Free Deliverability Help to All Businesses
• Paralegal Office of Shakira A. Lasisi Expands Legal, HR, and Administrative Consulting Services from
• Lady D Releases Chiseled by Choices: Reflections on Empowerment, Growth, and Healing
• MBF Productions Launches Spring Events on the CRAFTED at the Port of L.A. Grounds in San Pedro
• Hypnotherapy Finder Announces Official US Wide Launch After Successful Soft Launch

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Verrica suffered from manufacturing problems at its contract manufacturer's facility during bulk production of its lead product candidate, VP-102. These deficiencies had not been successfully remediated when the Company resubmitted its NDA for VP-102 to the FDA. This failure was likely to impact the chances of regulatory approval for the Company's product candidate. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Verrica, investors suffered damages.

More on The Californer

• Ayahuasca: The Mother Of All The Plants And The Voice Of Pachamama is now available for pre-order!
• Melzi Job Coach Launches on iOS and Android: A Privacy-First AI Career Engine Built for Execution
• "The Mystery of Emma Thorn" Earns Nomination & Official Selection of the New Media Film Festival
• Fresh Lifelines for Youth Appoints Laksmi Lagares as Vice President of Development
• RAW Marketing Agency Expands Nationwide Serving Small Businesses in Los Angeles, Miami and New York

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Contacts

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

---

Show All News | Report Violation